1. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.
- Author
-
Elessa, Dikélélé, Talbot, Alexis, Lombion, Naëlle, Harel, Stéphanie, Galicier, Lionel, Veyradier, Agnès, Joly, Bérangère, Andreoli, Annalisa, Rigaudeau, Sophie, Azoulay, Élie, Coppo, Paul, Royer, Bruno, and Arnulf, Bertrand
- Subjects
THROMBOTIC thrombocytopenic purpura ,ACTIVATED protein C resistance ,LITERATURE reviews ,IDIOPATHIC thrombocytopenic purpura ,PATHOLOGY - Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy (TMA) syndrome (Kremer et al. [8]). These three cases of TTP occurred during lenalidomide therapy (Table)- there was nothing that can usually be associated with thrombotic microangiopathy - no infectious trigger, no association with other autoimmune disorders, and no drugs intake. For our patients, the presence of anti-ADAMTS13 antibodies in each case and the efficacy of TPE and/or rituximab therapies imply an immune-mediated reaction. Montefusco et al. ([10]) described six autoimmune diseases after lenalidomide administration to 140 patients (4-3%): three autoimmune cytopenias and three organ-specific autoimmune disorders, occurring mostly in the first months of treatment. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF